IBDEI0TF ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14528,0)
 ;;=V15.07^^90^861^26
 ;;^UTILITY(U,$J,358.3,14528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14528,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,14528,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,14528,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,14529,0)
 ;;=V13.4^^90^861^27
 ;;^UTILITY(U,$J,358.3,14529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14529,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,14529,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,14529,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,14530,0)
 ;;=V12.72^^90^861^31
 ;;^UTILITY(U,$J,358.3,14530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14530,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,14530,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,14530,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,14531,0)
 ;;=V12.59^^90^861^30
 ;;^UTILITY(U,$J,358.3,14531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14531,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,14531,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,14531,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,14532,0)
 ;;=V45.81^^90^861^29
 ;;^UTILITY(U,$J,358.3,14532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14532,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,14532,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,14532,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,14533,0)
 ;;=V15.84^^90^861^28
 ;;^UTILITY(U,$J,358.3,14533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14533,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,14533,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,14533,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,14534,0)
 ;;=V15.85^^90^861^47
 ;;^UTILITY(U,$J,358.3,14534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14534,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,14534,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,14534,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,14535,0)
 ;;=V10.72^^90^861^34
 ;;^UTILITY(U,$J,358.3,14535,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14535,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,14535,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,14535,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,14536,0)
 ;;=V15.3^^90^861^35
 ;;^UTILITY(U,$J,358.3,14536,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14536,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,14536,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,14536,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,14537,0)
 ;;=V10.61^^90^861^37
 ;;^UTILITY(U,$J,358.3,14537,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14537,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,14537,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,14537,2)
 ;;=Hx of Lymphoid Leukemia^295232
 ;;^UTILITY(U,$J,358.3,14538,0)
 ;;=V12.03^^90^861^39
 ;;^UTILITY(U,$J,358.3,14538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14538,1,4,0)
 ;;=4^V12.03
 ;;^UTILITY(U,$J,358.3,14538,1,5,0)
 ;;=5^Hx of Malaria
 ;;^UTILITY(U,$J,358.3,14538,2)
 ;;=Hx of Malaria^303395
 ;;^UTILITY(U,$J,358.3,14539,0)
 ;;=V10.82^^90^861^40
 ;;^UTILITY(U,$J,358.3,14539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14539,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,14539,1,5,0)
 ;;=5^Hx of Malignant Melanoma
 ;;^UTILITY(U,$J,358.3,14539,2)
 ;;=Hx of Malignant Melanoma^295240
 ;;^UTILITY(U,$J,358.3,14540,0)
 ;;=V10.62^^90^861^43
 ;;^UTILITY(U,$J,358.3,14540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,14540,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,14540,1,5,0)
 ;;=5^Hx of Myeloid Leukemia
 ;;^UTILITY(U,$J,358.3,14540,2)
 ;;=Hx of Myeloid Leukemia^295233
 ;;^UTILITY(U,$J,358.3,14541,0)
 ;;=V10.63^^90^861^41
 ;;^UTILITY(U,$J,358.3,14541,1,0)
 ;;=^358.31IA^5^2
